Navigation Links
Cyprus and Ireland Add Wyeth's 7-Valent Pneumococcal Conjugate Vaccine (PCV7) to Their National Immunisation Schedules
Date:9/4/2008

MAIDENHEAD, England, September 4 /PRNewswire-FirstCall/ --

- Prevenar Vaccine to Help Protect Children Against the Leading Vaccine-Preventable Cause of Death in Young Children Worldwide

Wyeth today announced that Cyprus and the Republic of Ireland have initiated national immunisation programmes (NIPs) for infants and young children against pneumococcal disease by adding Prevenar(TM) (Pneumococcal Saccharide Conjugated Vaccine, Adsorbed), also called PCV7, to their national immunization schedules.(1) Including Ireland and Cyprus, this now makes 26 countries across the world that have included Prevenar in their NIPs.(1)

"Wyeth, the manufacturer of Prevenar, is pleased to be part of these initiatives and welcomes the introduction of this life-saving vaccine into national immunization schedules," says Dr E. David McIntosh, a paediatrician and European Medical Director, Infectious Diseases/Vaccines at Wyeth. "Wyeth is dedicated to the wellbeing of children and to continuing to work with governments and public health agencies to further expand access to Prevenar to help prevent serious and debilitating pneumococcal infections caused by serotypes contained in the vaccine. This includes facilitating the introduction of the vaccine in those countries that have announced their decision to include Prevenar in their national immunisation programmes but have yet to introduce the vaccine as part of their immunisation schedule."

Pneumococcal disease results in approximately 1.6 million deaths per year worldwide of which up to 1 million deaths are in children younger than five years of age.(2) Pneumococcal disease is the leading vaccine-preventable cause of death in children younger than five years of age worldwide.(3)

The World Health Organization (WHO) recommends priority inclusion of the 7-valent pneumococcal conjugate vaccine in national childhood immunization programs worldwide due to the significant burden of pneumococcal disease and demonstrated vaccine efficacy.(4) Recently, the Strategic Advisory Group of Experts (SAGE) to WHO issued a preliminary recommendation that pneumococcal disease prevention be ranked as a very high priority on a global basis.(5)

Prevenar(TM), the only licensed pneumococcal conjugate vaccine, is now available in 88 countries around the world, with more than 180 million doses distributed.(1)

Pneumococcal Disease

Pneumococcal disease affects both children and adults and is a leading cause of illness and death worldwide.(6) Pneumococcal disease is caused by the bacterium Streptococcus pneumoniae and describes a group of illnesses, including invasive infections, such as bacteremia/sepsis and meningitis, as well as pneumonia and upper respiratory tract infections, including otitis media.(7) Prevenar is the first and only pneumococcal conjugate vaccine approved to help protect infants and young children against pneumococcal disease caused by the serotypes included in the vaccine.(7)

Wyeth

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing and marketing of pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

References:

1) Data on file, Wyeth Pharmaceuticals Inc.

2) March 2007-WHO position paper

3) Health Protection Agency (HPA): Centre for Infections.

Cumulative weekly number of reports of invasive pneumococcal disease

Due to any of the seven serotypes present in PCV-7: children <2 years

In England and Wales by epidemiological year: July-June (2003 to

date). Cumulative Weekly Report IPD. February 2008.

4) World Health Organization. Pneumococcal conjugate vaccine for

childhood immunization, March 2007- WHO position paper. Wkly Epidemiol

Record 2007;12:93-104.

5) World Health Organization. Meeting of the immunization Strategic

Advisory Group of Experts, November 2007 - conclusions and

recommendations. Wkly Epidemiol Record 2008; (83): 1-16.

6) Centers for Disease Control and Prevention. Prevention of

pneumococcal disease: recommendations of the Advisory Committee on

Immunization Practices (ACIP). MMWR. 1997;46(RR-8):1-24. Available at:

5236. Accessed February 14, 2008.

7) Summary of Product Characteristics for PREVENAR, Wyeth

Pharmaceuticals, Inc.


'/>"/>
SOURCE Wyeth Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. SAFC Supports Potent API Conjugate Manufacturing With New St. Louis Production Suite
2. Global Experts Explore Entire Spectrum of Aids Vaccine Development
3. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
4. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
5. Anthrax vaccine produces immunity with nanoparticles, not needles
6. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
7. International Scientific Workshop Focuses on New Methods for Vaccine and Antibody Development
8. The University of Nottingham in the British Midlands Announces Development of Possible Hepatitis C Vaccine
9. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
10. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
11. Carrington Subsidiary DelSite Biotechnologies Enters into Technology Evaluation Rights License Agreement for Transdermal Delivery of Vaccines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 08, 2016 , ... Net-Translators, ... today the launch of its revamped and improved website. In an on-going effort ... the redesigned website will better communicate how the company designs and delivers thorough, ...
(Date:2/9/2016)... ... February 09, 2016 , ... The American Academy ... history, it is offering its 2016 AAT Member Certification Qualification Course for Technicians via ... for the webinar, which will include a detailed review of hardware, software, and camera ...
(Date:2/9/2016)...  DNAtrix, a clinical stage, biotechnology company ... its lead product, DNX-2401, has been designated ... medicinal product for the treatment of glioma. ... approximately 25,000 people a year in the ... --> http://photos.prnewswire.com/prnh/20160208/330986LOGO ...
(Date:2/9/2016)... Three-Year Initiative Supports Next Generation of Medical Geneticists ... Camp Experiences SHPG ... lives of children born with rare diseases, as well as the ... announcing a new initiative designed to positively affect the lives of ... rare disease care. --> To mark the company,s founding ...
Breaking Biology Technology:
(Date:1/22/2016)... , January 22, 2016 ... the addition of the  "Global Behavioral ... offering. --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) ... "Global Behavioral Biometric Market 2016-2020"  report ... Research and Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has ...
(Date:1/20/2016)... , Jan. 20, 2016   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... significant achievements are the result of the company,s laser ... iMedNet eClinical , it,s comprehensive, easy-to-use and highly ... --> Key MedNet growth achievements in 2015 ...
(Date:1/13/2016)... , January 13, 2016 ... has published a new market report titled - Biometric Sensors ... and Forecast, 2015 - 2023. According to the report, the global ... and is anticipated to reach US$1,625.8 mn by 2023, ... 2023. In terms of volume, the biometric sensors market ...
Breaking Biology News(10 mins):